Figure 3From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]Lipids up to 36 months since trial entry (adjusted for baseline differences between groups). (a) Total cholesterol; (b) LDL-cholesterol; (c) HDL-cholesterol; and (d) triglycerides.Back to article page